Citalopram hydrobromide

(HB2142)
Technical documents: SDS CoA Datasheet

Product overview

Name Citalopram hydrobromide
Alternative names Lu 10-171
Purity >98%
Description Potent, selective 5-HT uptake inhibitor
Write Your Own Review
You're reviewing:Citalopram hydrobromide
Rate this item:

Images

Figure 1. Citalopram increases positive feedback sensitivity in rats within a probabilistic reward learning task.

Citalopram is a SSRI, widely used to investigate 5-HT neurotransmission. Citalopram from Hello Bio increases positive feedback sensitivity in rats completing a probabilistic reward learning task (Rm-ANOVA, F3,47 = 3.8, p = 0.019).  For protocol see #Protocol 1 in Application Notes below.

Biological Data

Biological description

Potent, selective 5-HT uptake inhibitor (Ki = 0.75 nM at SERT and IC50 values are 1.8, ~8,000 and ~40,000 nM for 5-HT, noradrenaline and dopamine uptake respectively). Shows antidepressant effects. Active in vivo.

Application notes

Fig 1: Citalopram increases positive feedback sensitivity in rats within a probabilistic reward learning task.

Citalopram is a SSRI, widely used to investigate 5-HT neurotransmission. Citalopram from Hello Bio increases positive feedback sensitivity in rats completing a probabilistic reward learning task (see Fig 1 above, Rm-ANOVA, F3,47 = 3.8, p = 0.019).

 

#Protocol 1: Measurement of citalopram induced changes in positive feedback sensitivity within a probabilistic reward learning task.

  • Lister hooded rats were trained in the probabilistic reversal learning task (see Wilkinson et al, 2020)
  • Animals were injected with either 0, 1, 3 or 10 mg/kg citalopram in 0.9% saline intraperitoneally 30 minutes before a session.
  • All animals had all doses of citalopram in a blinded, fully counterbalanced and within subject design.
  • Positive feedback sensitivity was taken as win-stay probability: the probability that if an animal was rewarded at a stimulus they would return on the next trial.
  • Statistics: Rm-ANOVA, Main effect of treatment: F3,47 = 3.8, p = 0.019. Sidak corrected posthocs: 3mg/kg vs 0 mg/kg: t33 = 3.0, p = 0.013; 10mg/kg vs 0mg/kg: t33 = 2.6, p = 0.041

Solubility & Handling

Storage instructions Room temperature
Solubility overview

Soluble in water (10mM) and ethanol (50mM)

Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >98%
Chemical name 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitril e hydrobromide
Molecular Weight 405.31
Chemical structure Citalopram hydrobromide Chemical Structure
Molecular Formula C20H21FN2O.HBr
CAS Number 59729-32-7
PubChem identifier 77995
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br
InChi InChI=1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H
InChiKey WIHMBLDNRMIGDW-UHFFFAOYSA-N
MDL number MFCD02101306
Appearance White solid

References for Citalopram hydrobromide

References are publications that support the biological activity of the product
  • Preclinical pharmacology of citalopram.

    Popik P (1999) J Clin Psychopharmacol 19(5 Suppl 1) : 4S-22S.
  • Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

    Owens MJ et al (1997) J Pharmacol Exp Ther 283(3) : 1305-22.
  • Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.

    Hyttel J (1982) Prog Neuropsychopharmacol Biol Psychiatry 6(3) : 277-95.

3 Item(s)

Publications
These publications cite the use of Citalopram hydrobromide purchased from Hello Bio:
  • Investigating the Behavioural and Electrophysiological Consequences of Early Life Stress

    Wilkinson et al (2021) Bristol University : Thesis
  • Comparison of conventional and rapid-acting antidepressants in a rodent probabilistic reversal learning task.

    Wilkinson et al. (2020) Brain Neurosci Adv 4 : 1-11
    PubMedID: 32219179
  • Comparison of acute treatment with delayed-onset versus rapid-acting antidepressants on effort-related choice behaviour

    Griesius S et al (2020) Psychopharmacology (Berl) 237(8) : 2381-2394
    PubMedID: 32435818

3 Item(s)